Clinical Trials
ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Studies listed here represent active and ongoing clinical trials in the United States and Canada. Please click on the links for more information on each study including eligibility requirements and study locations. Studies listed are intended to provide a reference for trials related to rheumatologic skin disease, but the list is not comprehensive nor are the studies included specifically endorsed by RDS.
Lupus
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s) Wed, Feb 05, 2025
- CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry Fri, Jan 31, 2025
- Efficacy and Safety of HN2301 in Refractory Systemic Lupus Erythematosus (SLE) Thu, Jan 30, 2025
- Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus Tue, Jan 28, 2025
- The Anifrolumab PRIM Program Tue, Jan 28, 2025
- Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease Mon, Jan 27, 2025
- Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease Mon, Jan 27, 2025
Dermatomyositis
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Fri, Oct 17, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Fri, Oct 17, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Fri, Oct 17, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
Systemic sclerosis
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Fri, Oct 17, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
Morphea
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Fri, Oct 17, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
Vasculitis
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. Mon, Oct 05, 2274
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases Sat, Oct 13, 2040
- An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma Tue, Nov 28, 2028
- MEMRI and Kidney Disease Thu, Jan 22, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Wed, Dec 17, 2025
- Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Fri, Oct 17, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases Thu, Feb 06, 2025
Clinical Registries
Lupus:
Cutaneous Lupus Registry at University of Pennsylvania Medical Center in Philadelphia, PA
Dermatologists at Penn established a registry for cutaneous lupus patients in 2006 to gather the large number of patients necessary for studies to better understand the development of the disease and improve our methods of diagnosis, prognosis, and treatment. The database includes a blood and tissue bank CLE Tissue Bank, which was started at Penn in 2009 as a foundation for genetic, biomarker and pathophysiologic studies.
The principal investigator for the study is Victoria Werth, MD, Professor of Dermatology at the University of Pennsylvania, an expert in the treatment of cutaneous lupus. For more information, please go to
http://www.uphs.upenn.edu/dermatology/research-clinical-trials/clinical-trials.html
Cutaneous Lupus Registry at University of Texas Southwestern Medical Center in Dallas, TX
Dermatologists at UT Southwestern have established a registry for cutaneous lupus patients and their relatives in order to gather the large number of patients necessary for studies to better understand the development of the disease and improve our methods of diagnosis, prognosis, and treatment. This registry will provide a resource for investigators to make discoveries in regards to both the clinical and molecular aspects of the disease. The principal investigator for the study is Benjamin Chong, MD, assistant professor of dermatology at UT Southwestern, director of the connective tissue diseases clinic, and an expert in the treatment of cutaneous lupus. Participants will receive newsletters detailing the progress of the registry annually. Registration of study participants, which will require an in-person evaluation and consent, is already underway. For more information, please go to
Dermatomyositis:
Dermatomyositis Patient Registry at Stanford University Medical Center in Palo Alto, CA
We are interested in enrolling patients with dermatomyositis in order to better understand the disease and help find more effective and personalized therapies. Participants are asked to donate a blood sample as well as skin biopsy. If interested, please contact one of the two participating sites:
Stanford Department of Dermatology
Principal Investigator: David Fiorentino, MD, PhD
Contact: Amanda Foster
650-421-6103
Amfoster@stanford.edu
Dermatomyositis Patient Registry at University of Pennsylvania Medical Center in Philadelphia, PA
This is a study of dermatomyositis subjects who are followed during regularly scheduled clinic visits and are asked to provide data leading to evaluation of clinical responsiveness of their skin disease. Participants can donate a blood sample as well as skin biopsy. Studies relate to effectiveness of current treatments, studies to better understand the causes of the disease, and ways to improve treatments. If interested, please contact one of the two participating sites:
University of Pennsylvania
Principal Investigator: Victoria Werth, M.D.
Contact: Joyce Okawa
Phone: 215-898-0168
http://www.uphs.upenn.edu/dermatology/research-clinical-trials/clinical-trials.html